步长制药股票讨论区

Shandong Buchang Pharmaceuticals' low P/S ratio may reflect expectations of continued disappointing revenue performance. The company's declining revenue and predicted industry growth could challenge its current P/S ratio, potentially disappointing shareholders. Current investor sentiment and future expectations do not seem to justify a higher P/S ratio for the company.

The recent sell-off could be an opportunity, but it's recommended to check the fundamental data for signs of a long-term growth trend. There are also 2 warning signs for the company that should be considered.